[18F]4FN PET Imaging of Innate Immunity Activation During Immunotherapy-Induced Adverse Events
[18F]4FN PET 成像显示免疫治疗引起的不良事件期间先天免疫激活
基本信息
- 批准号:10501365
- 负责人:
- 金额:$ 52.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:Adverse eventAutoimmunityBiochemicalBiocompatible MaterialsBiological MarkersBiologyBiotechnologyCAR T cell therapyCancer PatientCellsCharacteristicsCollagen ArthritisCytometryDietDiseaseEffector CellGenerationsGoalsHematologic NeoplasmsHot SpotImageImmuneImmunologic MonitoringImmunological ModelsImmunotherapyInfiltrationInflammationInflammatoryInnate Immune SystemInvestigationIronKineticsKnowledgeMacrophage Colony-Stimulating FactorMediatingMetabolic syndromeModelingMolecularMonitorMonoclonal AntibodiesMyelogenousNADPH OxidaseNaphtholsNatural ImmunityNatureNeurotoxicity SyndromesNeutrophilic InfiltrateNitrogenOxidantsOxidation-ReductionOxidesOxygenParticipantPathway interactionsPatientsPeroxidasesPositron-Emission TomographyPre-Clinical ModelProcessProductionProteinsRadiopharmaceuticalsReactionReactive Oxygen SpeciesReagentReportingRoleSeriesSerumSerum MarkersSex DifferencesSignal TransductionSignaling MoleculeSuperoxidesTherapeuticTissue imagingTissuesToxic effectTumor ImmunityValidationbasebioluminescence imagingcheckpoint therapyclinical imagingclinical practicediagnostic valueexperiencefluorodeoxyglucosehumanized mouseimmune activationimmune checkpointimmune-related adverse eventsin vivoinhibiting antibodyinsightmacrophagemelanomamolecular imagingmouse modelneurotoxicityneutrophilnonalcoholic steatohepatitisnovelpre-clinicalradiotracerrecruitresponseside effectsmall moleculetumorwhole body imaging
项目摘要
ABSTRACT
While monoclonal antibodies inhibiting immune checkpoints (ICI) and CAR T-cell therapies have
dramatically changed the therapeutic options for many cancer patients, up to 60% of patients will experience
immune-related adverse events (irAE) depending on the tumor type and immunotherapy. Thus, many patients
treated with immunotherapy will not see long term benefit and therefore only suffer potential side effects (and
possibly hyper progression), and the importance of predicting and managing immunotherapy-related adverse
events has already been identified as a critical gap in knowledge and clinical practice. Significantly, a common
molecular node of integration between the various inflammatory mechanisms of irAE, particularly in the subacute
setting, focuses on spurious activation of the innate immune system. Recently, we reported the synthesis and
validation of 4-[18F]fluoro-1-naphthol ([18F]4FN), a novel redox-tuned radiopharmaceutical for the selective
imaging of high energy oxygen and nitrogen radical species (RONS) by PET/CT. [18F]4FN provides a convenient
reagent for rapid, quantitative whole-body imaging to identify and monitor inflammatory foci generated by NADPH
oxidase-2 (NOX2) and myeloperoxidase (MPO) of the innate immune system and multi-organ inflammation,
including immunotherapy-mediated irAE. Monitoring irAE by PET imaging is the long-term clinical imaging goal
of our line of investigation. Near-term, we propose to investigate the role of activated innate immunity in vivo by
combined molecular imaging and multiplexed analysis of tissues in mechanism-based pre-clinical murine models
of irAE for which we can enhance our understanding of the activation dynamics of innate immunity and gain
signals of efficacy.
摘要
而抑制免疫检查点(ICI)和CAR T细胞疗法的单抗
极大地改变了许多癌症患者的治疗选择,高达60%的患者将经历
免疫相关不良事件(IRAE)取决于肿瘤类型和免疫治疗。因此,许多患者
用免疫疗法治疗不会看到长期的益处,因此只会遭受潜在的副作用(和
可能是过度进展),以及预测和管理免疫治疗相关不良反应的重要性
这些事件已经被确定为知识和临床实践中的一个关键差距。值得注意的是,一个常见的
IRAE各种炎症机制之间整合的分子结点,特别是在亚急性
背景,重点是对天生免疫系统的虚假激活。最近,我们报道了合成和
新型氧化还原调谐放射性药物4-[18F]-1-萘酚([18F]4FN)的验证
高能氧氮自由基物种(RON)的PET/CT成像[18F]4FN提供了一种方便
用于快速、定量全身成像的试剂,用于识别和监测NADPH产生的炎性病灶
先天性免疫系统中的NOX2和MPO与多器官炎症,
包括免疫疗法介导的IRAE。用正电子发射计算机断层显像监测IRAE是临床长期的影像目标
我们的调查范围。近期,我们建议通过以下方式研究激活的先天免疫在体内的作用
基于机制的临床前小鼠模型中组织的联合分子成像和多重分析
因此,我们可以加深对先天免疫激活动力学的理解,从而获得
药效的信号。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sattva S Neelapu其他文献
Sattva S Neelapu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sattva S Neelapu', 18)}}的其他基金
[18F]4FN PET Imaging of Innate Immunity Activation During Immunotherapy-Induced Adverse Events
[18F]4FN PET 成像显示免疫治疗引起的不良事件期间先天免疫激活
- 批准号:
10689251 - 财政年份:2022
- 资助金额:
$ 52.65万 - 项目类别:
Enhancing antitumor immunity with anti-PD-1 antibody in follicular lymphoma.
利用抗 PD-1 抗体增强滤泡性淋巴瘤的抗肿瘤免疫力。
- 批准号:
7785888 - 财政年份:2010
- 资助金额:
$ 52.65万 - 项目类别:
Enhancing antitumor immunity with anti-PD-1 antibody in follicular lymphoma.
利用抗 PD-1 抗体增强滤泡性淋巴瘤的抗肿瘤免疫力。
- 批准号:
8007379 - 财政年份:2010
- 资助金额:
$ 52.65万 - 项目类别:
Antigen Discovery and Development of Tumor-Specific Lymphoma Immunotherapy
肿瘤特异性淋巴瘤免疫疗法的抗原发现和发展
- 批准号:
7394961 - 财政年份:2007
- 资助金额:
$ 52.65万 - 项目类别:
Antigen Discovery and Development of Tumor-Specific Lymphoma Immunotherapy
肿瘤特异性淋巴瘤免疫疗法的抗原发现和发展
- 批准号:
7623457 - 财政年份:2007
- 资助金额:
$ 52.65万 - 项目类别:
Antigen Discovery and Development of Tumor-Specific Lymphoma Immunotherapy
肿瘤特异性淋巴瘤免疫疗法的抗原发现和发展
- 批准号:
7807105 - 财政年份:2007
- 资助金额:
$ 52.65万 - 项目类别:
相似海外基金
Thymus antibody-secreting cells: major players in autoimmunity.
胸腺抗体分泌细胞:自身免疫的主要参与者。
- 批准号:
502578 - 财政年份:2024
- 资助金额:
$ 52.65万 - 项目类别:
B cell development, autoimmunity and immune regulation
B 细胞发育、自身免疫和免疫调节
- 批准号:
MR/Y033701/1 - 财政年份:2024
- 资助金额:
$ 52.65万 - 项目类别:
Research Grant
Applying advanced understanding of CTLA-4 function to optimise therapies for autoimmunity
应用对 CTLA-4 功能的深入理解来优化自身免疫疗法
- 批准号:
MR/Y001273/1 - 财政年份:2024
- 资助金额:
$ 52.65万 - 项目类别:
Research Grant
MUC16 (CA125) mutations promote fibrosis and autoimmunity in systemic sclerosis
MUC16 (CA125) 突变促进系统性硬化症的纤维化和自身免疫
- 批准号:
478933 - 财政年份:2023
- 资助金额:
$ 52.65万 - 项目类别:
Operating Grants
Development of serologic test for early risk stratification of islet autoimmunity in genetically predisposed T1D individuals
开发用于遗传易感性 T1D 个体胰岛自身免疫早期风险分层的血清学检测
- 批准号:
10760885 - 财政年份:2023
- 资助金额:
$ 52.65万 - 项目类别:
Mechanisms of New-Onset Autoimmunity/Longitudinal Immune Systems Analysis (MONA-LISA)
新发自身免疫/纵向免疫系统分析(MONA-LISA)的机制
- 批准号:
10655219 - 财政年份:2023
- 资助金额:
$ 52.65万 - 项目类别:
Autoimmunity-Associated B Cells in Lupus Nephritis
狼疮性肾炎中自身免疫相关的 B 细胞
- 批准号:
10582053 - 财政年份:2023
- 资助金额:
$ 52.65万 - 项目类别:
Heparan sulfate as a platform to boost regulatory T cell suppression of autoimmunity
硫酸乙酰肝素作为增强调节性 T 细胞抑制自身免疫的平台
- 批准号:
490663 - 财政年份:2023
- 资助金额:
$ 52.65万 - 项目类别:
Operating Grants
The interplay of sex hormones and chromosomes dictates pathogenicity in progressive CNS autoimmunity.
性激素和染色体的相互作用决定了进行性中枢神经系统自身免疫的致病性。
- 批准号:
488982 - 财政年份:2023
- 资助金额:
$ 52.65万 - 项目类别:
Operating Grants
Understanding autoimmunity: Why do B cells sometimes attack our tissues instead of protecting us from infections?
了解自身免疫:为什么 B 细胞有时会攻击我们的组织而不是保护我们免受感染?
- 批准号:
2889164 - 财政年份:2023
- 资助金额:
$ 52.65万 - 项目类别:
Studentship